All In Biotech

Drug Trial Radar · NCT02105961

Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)

Study MEA117113: Mepolizumab vs. Placebo as Add-on Treatment for Frequently Exacerbating COPD Patients Characterized by Eosinophil Level

Last checked: Nov 20, 2026Latest source record: Aug 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 674 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

674

Actual

Start

Apr 24, 2014

Primary completion

Jan 16, 2017

Study completion Jan 16, 2017

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Apr 7, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-centered, randomized, placebo-controlled, double-blind, parallel group, trial evaluating 2 doses of mepolizumab against placebo given every 4 weeks through subcutaneous (SC) injection. In severe COPD subjects, sputum eosinophils levels are elevated to similar levels as those seen in severe asthmatics. It is hypothesized that the reduction of eosinophils with mepolizumab in COPD subjects would translate into a reduction of COPD exacerbations. The study will evaluate the efficacy and safety of mepolizumab, in subjects who are at or above the baseline blood eosinophil count of at least 150 cells/microliters who exacerbate despite regular use of maximal tolerated therapy, appropriate for severe COPD subjects, in the 12 months prior to study start. In total, 660 subjects will be randomized in 1:1:1 ratio to receive mepolizumab 300 mg, mepolizumab 100mg, or placebo administered SC. The total duration of subject participation will be approximately 62 weeks, consisting of a 1 to 2 week screening period, 52-week treatment period and 8-week follow-up period.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • MepolizumabDrug

    Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.

  • PlaceboDrug

    Sterile 0.9percent sodium chloride solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Moderate or Severe ExacerbationsTime frame: From randomization to Week 52

Locations

169 sites in 15 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Mobile, Alabama

  • GSK Investigational Site

    Riverside, California

  • GSK Investigational Site

    Upland, California

  • GSK Investigational Site

    Broomfield, Colorado

  • GSK Investigational Site

    Stamford, Connecticut

  • GSK Investigational Site

    Boynton Beach, Florida

  • GSK Investigational Site

    DeLand, Florida

  • GSK Investigational Site

    Edgewater, Florida

  • GSK Investigational Site

    Gainesville, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    St. Petersburg, Florida

  • GSK Investigational Site

    Adairsville, Georgia

  • GSK Investigational Site

    Duluth, Georgia

  • GSK Investigational Site

    Woodstock, Georgia

  • GSK Investigational Site

    Coeur d'Alene, Idaho

  • GSK Investigational Site

    Bowling Green, Kentucky

  • GSK Investigational Site

    Albuquerque, New Mexico

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Gastonia, North Carolina

  • GSK Investigational Site

    Huntersville, North Carolina

  • GSK Investigational Site

    Columbus, Ohio

  • GSK Investigational Site

    Portland, Oregon

  • GSK Investigational Site

    Hershey, Pennsylvania

  • GSK Investigational Site

    Oaks, Pennsylvania

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Charleston, South Carolina

  • GSK Investigational Site

    Easley, South Carolina

  • GSK Investigational Site

    Greenville, South Carolina

  • GSK Investigational Site

    Mt. Pleasant, South Carolina

  • GSK Investigational Site

    Rock Hill, South Carolina

  • GSK Investigational Site

    Fort Worth, Texas

  • GSK Investigational Site

    Richmond, Virginia

  • GSK Investigational Site

    Richmond, Virginia

  • GSK Investigational Site

    Morgantown, West Virginia

  • GSK Investigational Site

    Berazategui, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Mendoza, Argentina

  • GSK Investigational Site

    Mendoza, Argentina

Showing 40 of 169 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.